Signant Health Partners with Propeller Health


Applied Clinical Trials

Signant Health has announced a partnership to connect TrialMax, the electronic Clinical Outcome Assessment (eCOA) platform, to Propeller Health’s digital health platform for asthma and COPD (chronic obstructive pulmonary disease).

The partnership will help drive patient adherence to inhaled medications by enabling accurate time tracking of patients’ medication use events alongside their eDiary data within a single eCOA platform. Sponsors, CROs, and academic institutions can use this information to identify how patients are following treatment plans and identify occurrences when symptoms are triggered.

As always, TrialMax users benefit from a workflow presented intuitively in a single workspace. Sites and sponsors can view and report on medication use alongside clinical outcomes while study participants experience a simple and burden-free trial, as the Propeller sensors automatically track rescue and controller medication inhaler use. This level of insight allows researchers to track how populations are using inhalers, while still providing insight to oversee the progress and care of individual patients as needed. 

Bill Byrom, Signant Health’s VP Product Strategy & Innovation, said, “This integration is important in understanding inhaler use and patterns in patients with respiratory illnesses.  This will enable researchers to relate medication usage to responses to treatment, and for site personnel to gain deeper insights together with eCOA data to enhance patient oversight between clinic visits, in addition to encouraging medication adherence where appropriate.  The addition of the Propeller sensor within TrialMax’s ecosystem of connected wearables and sensors provides a frictionless way to collect medication usage data without requiring additional actions by the patient.  The Propeller Health partnership is an important addition to our solutions for patient-facing technology to enhance data collection and insights in clinical trials in respiratory illnesses.”  

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.